Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nuvation Bio Q3 2026 Results: Net Loss of $41.9M, Loss Narrows

Nuvation Bio Inc. reported financial results for the third quarter of 2026, highlighting continued progress in its clinical oncology programs. The company maintained a robust cash position to support operations through 2028, while reporting a net loss driven by ongoing research and development expenses.

Watch the Nuvation Bio Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue45.013.1
Profit before tax-41.9-55.8
Net income-41.9-55.8
EPS (diluted, $ a share)$-0.12$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+242.6%
Operating margin-93.9%
Source

10-Q filed with the SEC, NYSE: NUVB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nuvation Bio Inc.: key numbers

Share price
$3.84Close, Nov 16
Market cap
$1.36B
Shares outstanding
353.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nuvation Bio Inc.

All →
4:18 PM ET 8-K
Financial Results

Nuvation Bio Financial Results

Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.

“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”

David Hung, M.D., Founder, President, and Chief Executive Officer

“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”

David Hung, M.D., Founder, President, and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.